AnTaimmu BioMed Co., Ltd., founded in Apr. 2018 is a new drug discovery company focusing on developing novel therapeutic antibodies and protein drugs. The headquarter locates in Hsinchu Science Park of Taiwan since Jul. 2020. Our primary goal is to develop novel immunotherapy antibody drugs for cancer with enhanced efficiency and fewer side effects. Based on our bioinformatics and protein science technologies, we have constructed human synthetic antibody libraries, naive antibody libraries, and antibody libraries from immunized animals for screening specific monoclonal antibodies of cancer target molecules.
As a biologics drug development company, we will develop our drug until an early phase of the clinical trial and then cooperate with an international pharmaceutical company to complete the clinical drug development. We value humanity and are committed to improving human health. The final goal for AnTaimmu is to become the leading provider of antibody therapy.
Currently, our company has three main focuses: The first is the diagnostic and therapeutic antibodies for COVID-19. Since the outbreak of COVID-19, We are also dedicated to developing SARS CoV-2 neutralizing antibodies and have screened several candidates with high affinity and neutralization ability. We are constructing the candidates into the form of Neobody™, which is designed to bind to multiple different epitopes on SARS CoV-2 spike protein, preventing virus escape mutation. ATBM also partners with PBF and Eirgenix and launched Vstrip COVID-19 antigen rapid test in the middle of 2020.
The second is therapeutic antibodies for Cancer Therapy, especially for blood cancer. We are developing Neobody™, a new generation multivalent antibody, which enhances the capability of our immune system to detect and destroy tumor cells and avoids attacks on normal cells. At last, we also provide antibody and protein services, including gene cloning form hybridoma, antibody humanization, monoclonal antibody production, customized monoclonal antibodies, and antibody affinity maturation for academic institutions and pharmaceutical companies.
In the early stage, we focused on core technology setup and development. Here we designed and constructed a fully human synthetic antibody library based on phage display platforms. The immunized antibody libraries from rabbit and alpaca sources were also developed and validated. We also set up the stable clone of the mammalian protein expression system, cell-based functional assay, and animal model for drug efficacy evaluation. Finally, we also developed the product for COVID-19 antigen rapid test and neutralization antibodies detection.
In the current stage, the development of broad-spectrum therapeutic antibodies for COVID-19, new therapeutic antibodies for blood cancer, and novel format antibody drugs are three main corporate objectives. In the future, we will continually make efforts to drug development for other cancer and neuron degeneration disease. In vitro companion diagnostics device is another important direction for AnTaimmu.